An Open-Label, Multicenter Study to Assess the Safety of RO5185426 (Vemurafenib) in Patients With Metastatic Melanoma
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- Sponsors Roche
- 04 Apr 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 01 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 01 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.